Research programme: opioid receptor like-1 antagonists - Brane Discovery

Drug Profile

Research programme: opioid receptor like-1 antagonists - Brane Discovery

Alternative Names: 819555; 848814; BND-001; BND-1 programme; GSK 819555; GSK 848814; NiK-001; ORL-1 orphan receptor antagonists; ORL-1 programme; SB 612111

Latest Information Update: 11 Feb 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer Brane Discovery
  • Class Small molecules
  • Mechanism of Action Adenylate cyclase stimulants; Calcium channel agonists; G protein-coupled receptor antagonists; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued CNS disorders; Neuropathic pain; Parkinson's disease

Most Recent Events

  • 12 Jun 2007 This programme is available for partnership opportunities (http://www.branediscovery.com)
  • 04 Jun 2007 Brane Discovery acquires this research programme from NiKem Research
  • 04 Jun 2007 Preclinical trials in Parkinson's disease in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top